search
Back to results

Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.

Primary Purpose

Varicose Ulcer

Status
Completed
Phase
Phase 4
Locations
France
Study Type
Interventional
Intervention
Dressing
Dressing
Sponsored by
Laboratoires URGO
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Varicose Ulcer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient over 18 years old who has provided his/her written informed consent
  • Patient who can be monitored by the same investigation team throughout the duration of the study
  • Patient who agrees to wear effective venous compression every day, associated with the trial dressing
  • Leg ulcer with a distal Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3
  • Ulcer with a minimum area of 3 cm2 and a maximum area of 30 cm2
  • Ulcer duration between 3 and 36 months
  • Ulcer where the surface area is 70% or more covered by fibrinous tissue
  • Ulcer at least 3 cm away from any other lesion
  • Ulcer moderately or strongly exudative justifying the use of an absorbent dressing

Exclusion Criteria:

  • Female patient of child-bearing potential who has no effective means of contraception
  • Patient who is pregnant or breastfeeding
  • Patient taking part in another therapeutic trial
  • Patient with hypersensitivity to one of the components of the trial dressing or a known allergy to carboxymethylcellulose (hydrocolloid)
  • Patient with a serious general pathological condition who, it may be feared, might discontinue participation in the trial before the six weeks of treatment
  • Patient with an evolving neoplastic condition, treated by radiotherapy, chemotherapy or hormone therapy
  • Patient with a systemic infection not controlled by suitable antibiotic treatment
  • Patient who, during the 3 months before inclusion, presented a deep vein thrombosis
  • Ulcer where its surface is totally or partially covered by black necrotic plaque
  • Ulcer which is clinically infected
  • Ulcer requiring surgical treatment or for which surgery is programmed during the six weeks following inclusion
  • Malignant ulcer

Sites / Locations

  • Hopital Rothschild

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

URGO 310 3082

Aquacel

Arm Description

Outcomes

Primary Outcome Measures

The efficacy of dressings under trial will be judged on the evolution of wound surface area after six weeks of treatment.
The main evaluation criterion is the relative planimetric regression of the wound surface area, calculated according to the following formula, from centralised planimetric measurements: Regression of the area (%) = [(ST0-STlast)/ST0] x 100 ST0: Surface area of the lesion measured on the day of inclusion STlast: Surface area of the lesion at the last planimetric evaluation available

Secondary Outcome Measures

Comparison between the two devices of percentage of lesions in which the evolution is positive (defined by a relative regression at least 40% of wound surface) after monitoring for 6 weeks.
Comparison between the two groups of percentage of debrided lesions (defined by a lesion with more than 70% of its surface covered by granulation tissue of a "red colour" on the colorimetric scale), at the last available evaluation
Comparison between the two strategies of percentage of patients in whom at least one problem of pain was detected during care (VAS score at the end of care > 30 mm)
Comparison between the 2 groups of the percentage of wound care associated with manual debridement
Comparison between the two groups of the evolution of the patients' quality of life between inclusion and the last available visit. This quality of life will be assessed using the EuroQol-5D™ questionnaire
Comparison between the 2 groups of the percentage of the participants number with Adverse Events
Comparison between the 2 groups of the mean number of dressing changes per week.
Comparison between the 2 groups of the easiness application and removal
Comparison between the 2 groups of the percentage of good or very good conformability
Comparison between the 2 groups of the mean value for overall performance score
This score will be between 0 and 36

Full Information

First Posted
October 3, 2011
Last Updated
March 28, 2013
Sponsor
Laboratoires URGO
search

1. Study Identification

Unique Protocol Identification Number
NCT01449422
Brief Title
Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.
Official Title
Evaluation Of The Efficacy, Tolerance And Acceptability Of URGO Dressing 310 3082 Versus A Hydrofibre Dressing In The Local Management Of Venous Or Predominantly Venous Mixed Leg Ulcers
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laboratoires URGO

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main objective of this trial is to demonstrate that a local care strategy using URGO 310 3082 dressing is not inferior to a reference therapeutic strategy using a hydrofibre dressing in the management of venous ulcers. This non-inferiority hypothesis will be judged on the planimetric relative regression of the wound surface area after six weeks of treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Varicose Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
159 (Actual)

8. Arms, Groups, and Interventions

Arm Title
URGO 310 3082
Arm Type
Experimental
Arm Title
Aquacel
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Dressing
Intervention Description
the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
Intervention Type
Device
Intervention Name(s)
Dressing
Intervention Description
the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
Primary Outcome Measure Information:
Title
The efficacy of dressings under trial will be judged on the evolution of wound surface area after six weeks of treatment.
Description
The main evaluation criterion is the relative planimetric regression of the wound surface area, calculated according to the following formula, from centralised planimetric measurements: Regression of the area (%) = [(ST0-STlast)/ST0] x 100 ST0: Surface area of the lesion measured on the day of inclusion STlast: Surface area of the lesion at the last planimetric evaluation available
Time Frame
Week 1, 2, 4 and 6
Secondary Outcome Measure Information:
Title
Comparison between the two devices of percentage of lesions in which the evolution is positive (defined by a relative regression at least 40% of wound surface) after monitoring for 6 weeks.
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the two groups of percentage of debrided lesions (defined by a lesion with more than 70% of its surface covered by granulation tissue of a "red colour" on the colorimetric scale), at the last available evaluation
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the two strategies of percentage of patients in whom at least one problem of pain was detected during care (VAS score at the end of care > 30 mm)
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the 2 groups of the percentage of wound care associated with manual debridement
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the two groups of the evolution of the patients' quality of life between inclusion and the last available visit. This quality of life will be assessed using the EuroQol-5D™ questionnaire
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the 2 groups of the percentage of the participants number with Adverse Events
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the 2 groups of the mean number of dressing changes per week.
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the 2 groups of the easiness application and removal
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the 2 groups of the percentage of good or very good conformability
Time Frame
Week 1, 2, 4 and 6
Title
Comparison between the 2 groups of the mean value for overall performance score
Description
This score will be between 0 and 36
Time Frame
Week 1, 2, 4 and 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient over 18 years old who has provided his/her written informed consent Patient who can be monitored by the same investigation team throughout the duration of the study Patient who agrees to wear effective venous compression every day, associated with the trial dressing Leg ulcer with a distal Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3 Ulcer with a minimum area of 3 cm2 and a maximum area of 30 cm2 Ulcer duration between 3 and 36 months Ulcer where the surface area is 70% or more covered by fibrinous tissue Ulcer at least 3 cm away from any other lesion Ulcer moderately or strongly exudative justifying the use of an absorbent dressing Exclusion Criteria: Female patient of child-bearing potential who has no effective means of contraception Patient who is pregnant or breastfeeding Patient taking part in another therapeutic trial Patient with hypersensitivity to one of the components of the trial dressing or a known allergy to carboxymethylcellulose (hydrocolloid) Patient with a serious general pathological condition who, it may be feared, might discontinue participation in the trial before the six weeks of treatment Patient with an evolving neoplastic condition, treated by radiotherapy, chemotherapy or hormone therapy Patient with a systemic infection not controlled by suitable antibiotic treatment Patient who, during the 3 months before inclusion, presented a deep vein thrombosis Ulcer where its surface is totally or partially covered by black necrotic plaque Ulcer which is clinically infected Ulcer requiring surgical treatment or for which surgery is programmed during the six weeks following inclusion Malignant ulcer
Facility Information:
Facility Name
Hopital Rothschild
City
Paris
ZIP/Postal Code
75012
Country
France

12. IPD Sharing Statement

Learn more about this trial

Clinical Trial to Evaluate the Efficacy, Tolerance and Acceptability of URGO Dressing vs a Hydrofibre in the Local Management of Venous or Predominantly Venous Mixed Leg Ulcers.

We'll reach out to this number within 24 hrs